LITS
Lite Strategy Inc
NASDAQ · Biotechnology
$1.06
+0.11 (+11.45%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.33M | 11.14M | 10.37M |
| Net Income | -3,474,981 | -2,537,744 | -2,319,778 |
| EPS | — | — | — |
| Profit Margin | -28.2% | -22.8% | -22.4% |
| Rev Growth | +17.2% | +1.6% | +25.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 10.90M | 9.07M | 11.40M |
| Total Equity | 31.89M | 31.43M | 33.01M |
| D/E Ratio | 0.34 | 0.29 | 0.35 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -5,324,397 | -5,017,327 | -4,875,631 |
| Free Cash Flow | -1,460,004 | -1,340,766 | -1,751,994 |